New immunotherapy combo may let older colon cancer patients skip surgery
NCT ID NCT06205836
First seen Dec 12, 2025 · Last updated May 22, 2026 · Updated 23 times
Summary
This study tests whether two immunotherapy drugs, cemiplimab alone or combined with fianlimab, can eliminate tumors in older adults (age 70+) or those unfit for surgery with a specific genetic type of colorectal cancer (MSI-H). The goal is to achieve a complete response, meaning no cancer is found on scans or after surgery, allowing patients to avoid or delay surgery. The trial enrolls 44 participants and monitors them for 24 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins SKCCC
RECRUITINGBaltimore, Maryland, 21231, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.